Gilead SciencesÂ (NASDAQ:GILD) released more positive results relating to remdesivir and its effectiveness in battling COVID-19 earlier this month.Let's take a closer look to see whether investors are missing out on a great opportunity here, or if remdesivir's results aren't enough to make Gilead's stock a buy.